CMS 2026 ASP Reporting Update: Reasonable Assumptions Form Due April 30

Under the 2026 CMS Final Rule, pharmaceutical manufacturers face a new compliance requirement: beginning with Q1 2026 ASP reporting, manufacturers must submit a Reasonable Assumptions Form alongside their Average Sales Price (ASP) data.

The first submission is due April 30, 2026.

While most manufacturers already maintain internal SOPs governing ASP methodology and Government Pricing controls, CMS is now requiring those assumptions to be formally summarized and submitted in a standardized format. What was previously internal documentation is now an explicit regulatory disclosure subject to review and verification.

This represents a meaningful shift in CMS ASP reporting oversight.

What Changed Under the 2026 CMS Final Rule?

CMS is increasing transparency and verification requirements around ASP reporting. Manufacturers must now:

• Document the reasonable assumptions used in ASP calculations
• Submit those assumptions directly to CMS
• Ensure alignment between written policies and system logic
• Confirm operational consistency across finance, pricing, and Government Pricing teams

The Reasonable Assumptions Form elevates methodology documentation from background governance to front-facing regulatory disclosure.

Why This Raises Compliance Risk

The compliance risk does not stem from new pricing methodologies. It arises from inconsistency.

Common risk areas include:

• Bona Fide Service Fee Assessment and Application
• Disconnects between written SOPs and system configuration
• Legacy assumptions embedded in ERP or Government Pricing systems
• Inconsistent treatment of chargebacks, rebates, or fee calculations
• Narrative disclosures that do not fully reflect operational execution

CMS now expects the submitted assumptions to be accurate, concise, and defensible. Discrepancies between policy, process, and system output create avoidable exposure.

Preparing for the April 30, 2026 ASP Deadline

With Q1 2026 ASP reporting due April 30, preparation should already be underway.

Manufacturers should:

1. Conduct a structured review of existing ASP methodologies
2. Reconcile written SOPs with system configuration and actual data flow
3. Validate cross-functional alignment across pricing, finance, and compliance
4. Draft and refine Reasonable Assumptions Form responses early

This is not about rewriting ASP methodology. It is about ensuring regulatory disclosure reflects operational reality and that those operational processes are well documented.

For a deeper technical breakdown of the 2026 CMS Final Rule and expanded ASP reporting requirements, read our detailed analysis: 2026 CMS Final Rule: Expanded ASP Reporting and Verification Requirements for Manufacturers.

How We Support CMS ASP Compliance

Prescription Analytics provides focused expertise in:

• Government Pricing operations
• ASP reporting and validation
• CMS compliance readiness
• Methodology documentation and defensibility

We partner with pharmaceutical manufacturers to assess overall Government Pricing readiness, strengthen documentation and internal controls, and ensure submissions are accurate, consistent, and defensible under evolving CMS requirements, including the April 30 ASP reporting deadline.

If your organization is evaluating its broader Government Pricing compliance framework in light of the 2026 updates, we welcome a discussion regarding scope and next steps.